According to an FTC report, PBMs are central to the complex pharmaceutical distribution chain that delivers medicines from manufacturers to patients. PBMs serve as middlemen, negotiating the terms and conditions for prescription access. Those who work in the industry know this, but the critical question is, “What’s going to be done about it?”

Few entities have as significant an impact on drug costs in the intricate web of the American healthcare system as Pharmacy Benefit Managers (PBMs). Established to streamline drug benefits for insurers and employers, PBMs have evolved into powerful intermediaries with substantial influence over which drugs are covered and at what price. The job of the P.B.M.s is to reduce drug costs. Instead, they frequently do the opposite. They steer patients toward pricier drugs, charge steep markups on what would otherwise be inexpensive medicines, and extract billions of dollars in hidden fees.

The intersection of profit and patient care in the healthcare industry has become contentious in recent years. For healthcare workers, balancing running a financially viable institution and providing affordable care is a daily challenge. Let’s delve into whether the pursuit of profit in healthcare has overshadowed our primary mission: helping patients afford the treatments they need.

Patents play a crucial role in protecting intellectual property and fostering innovation. However, over the years, the pharmaceutical industry has been criticized for manipulating the patent system to extend its monopoly on drugs, keeping prices high, and limiting access to essential medications. This blog post delves into the tactics employed by Big Pharma to exploit the patent system, the impact on consumers and healthcare, and the potential solutions to address these abuses.

According to the Financial Times, a country’s economy can benefit from spending on healthcare, even if the health outcomes are not excellent. In the United States, spending on healthcare is high, but the health outcomes are not good. This could mean that the healthcare system is inefficient and not very effective. So, we should be careful when we say an economy is vital because we need to understand where the money is going and why.

In the land of the free and the home of the brave, the American dream often includes visions of prosperity, success, and a long, healthy life. However, the reality for many Americans is quite different. An alarming number of individuals are caught in a cycle of unhealthy habits that not only deteriorate their quality of life but also place a significant financial strain on the nation’s healthcare system. The cost of unhealthy lifestyles is staggering, and it’s time to address the root causes to create a healthier future for all.

The NIH identified 273 drugs in a review of FDA oncologic drug approvals. After applying exclusion criteria, 224 cancer drug approvals across 119 individual drugs were analyzed. Across all tumor types, the median annual cost for a course of an anticancer drug was $196,000 (IQR, $170,000-$277,000). As ASCO begins in Chicago, there will be a lot of PR targeted at Wall Street analysts but minimal discussion about the cost of cancer drugs.